1 |
Januškevičienė I, Petrikaitė V. Heterogeneity of breast cancer: the importance of interaction between different tumor cell populations[J]. Life Sci, 2019, 239: 117009.
|
2 |
Gooding AJ, Zhang B, Gunawardane L, et al. The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers[J]. Oncogene, 2019, 38(12): 2020-2041.
|
3 |
Testa U, Castelli G, Pelosi E. Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments[J]. Med Sci (Basel), 2020, 8(1): E18.
|
4 |
Murayama T, Gotoh N. Patient-derived xenograft models of breast cancer and their application[J]. Cells, 2019, 8(6): E621.
|
5 |
Ishiguro T, Ohata H, Sato A, et al. Tumor-derived spheroids: relevance to cancer stem cells and clinical applications[J]. Cancer Sci, 2017, 108(3): 283-289.
|
6 |
Rosenbluth JM, Schackmann RCJ, Kenneth Gray G, et al. Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages[J]. Nat Commun, 2020, 11: 1711.
|
7 |
Drost J, Clevers H. Organoids in cancer research[J]. Nat Rev Cancer, 2018, 18(7): 407-418.
|
8 |
Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018, 172(1/2): 373-386.e10.
|
9 |
Calar K, Plesselova S, Bhattacharya S, et al. Human plasma-derived 3D cultures model breast cancer treatment responses and predict clinically effective drug treatment concentrations[J]. Cancers, 2020, 12(7): 1722.
|
10 |
Zhang L, Adileh M, Martin ML, et al. Establishing estrogen-responsive mouse mammary organoids from single Lgr5+ cells[J]. Cell Signal, 2017, 29: 41-51.
|
11 |
Houthuijzen JM, Jonkers J. Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment[J]. Cancer Metastasis Rev, 2018, 37(4): 577-597.
|
12 |
Truong DD, Kratz A, Park JG, et al. A human organotypic microfluidic tumor model permits investigation of the interplay between patient-derived fibroblasts and breast cancer cells[J]. Cancer Res, 2019, 79(12): 3139-3151.
|
13 |
Nayak B, Balachander GM, Manjunath S, et al. Tissue mimetic 3D scaffold for breast tumor-derived organoid culture toward personalized chemotherapy[J]. Colloids Surf B Biointerfaces, 2019, 180: 334-343.
|
14 |
Richards Z, McCray T, Marsili J, et al. Prostate stroma increases the viability and maintains the branching phenotype of human prostate organoids[J]. iScience, 2019, 12: 304-317.
|
15 |
Liu J, Shen JX, Wu HT, et al. Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target[J]. Discov Med, 2018, 25(139): 211-223.
|
16 |
Kauppila S, Stenbäck F, Risteli J, et al. Aberrant type Ⅰ and type Ⅲ collagen gene expression in human breast cancer in vivo[J]. J Pathol, 1998, 186(3): 262-268.
|
17 |
Zhu YY, Chen C, Li JJ, et al. The prognostic value of quantitative analysis of CCL5 and collagen Ⅳ in luminal B (HER2-) subtype breast cancer by quantum-dot-based molecular imaging[J]. Int J Nanomedicine, 2018, 13: 3795-3803.
|
18 |
Carranza-Rosales P, Guzmán-Delgado NE, Carranza-Torres IE, et al. Breast organotypic cancer models[J]. Curr Top Microbiol Immunol, 2018. DOI:10.1007/82_2018_86.
|
19 |
Drost J, van Boxtel R, Blokzijl F, et al. Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer[J]. Science, 2017, 358(6360): 234-238.
|
20 |
Duarte AA, Gogola E, Sachs N, et al. BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance[J]. Nat Methods, 2018, 15(2): 134-140.
|
21 |
Kondo J, Inoue M. Application of cancer organoid model for drug screening and personalized therapy[J]. Cells, 2019, 8(5): E470.
|
22 |
Bager CL, Willumsen N, Leeming DJ, et al. Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: a preliminary study[J]. Cancer Biomark, 2015, 15(6): 783-788.
|
23 |
Rios AC, Clevers H. Imaging organoids: a bright future ahead[J]. Nat Methods, 2018, 15(1): 24-26.
|
24 |
Mazzucchelli S, Piccotti F, Allevi R, et al. Establishment and morphological characterization of patient-derived organoids from breast cancer[J]. Biol Proced Online, 2019, 21: 12.
|
25 |
Yu J, Huang W. The progress and clinical application of breast cancer organoids[J]. Int J Stem Cells, 2020, 13(3): 295-304.
|
26 |
Su SC, Chen JN, Yao HR, et al. CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness[J]. Cell, 2018, 172(4): 841-856.e16.
|
27 |
Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer[J]. Cancer Cell, 2018, 33(3): 463-479.e10.
|